SCHOTT is planning to triple its ready-to-use vial production capacity in the United States to meet increasing demand for storing injectable drugs.
SCHOTT has announced plans to triple its ready-to-use vial production capacity at its site in Lebanon, PA, to meet increasing demand for storing injectable drugs. The company currently provides a comprehensive product portfolio for ready-to-use vials with more than 750 product combinations.
Ready-to-use vials are particularly suitable for drugs, such as biologics and vaccines. The vials are pre-washed and sterilized and packaged in a standardized tub to simplify the filling process for pharmaceutical companies. The solution enables pharma companies to efficiently perform pre-clinical and clinical trials as well as commercial filling.
“With our investment, we are underlining our commitment to the global pharma industry and particularly the U.S. market. Additionally, we are enhancing our regional manufacturing footprint in Lebanon, Pennsylvania, where we are proudly celebrating our site’s 30th anniversary,” said Andreas Reisse, executive vice president of SCHOTT Pharma, in a press release.
“We are increasing our production capacity intending to meet the growing need for this product category and contribute to bringing the latest life-saving treatments to patients faster,” said Hakan Gerdan, who was appointed as SCHOTT’s new Plant Manager in Lebanon, PA at the start of 2022, in the release.
Source: SCHOTT
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.